



CARE SERVICES UPDATE



Dear Administrative Agency (AA) and Planning staff, see below for important announcements:

- 1) Relocation of HIV/STD/TB Program Staff
- 2) Ryan White Administrative Agency, Service Delivery Renewal 2018-2019
- 3) Frequently Asked Questions (FAQ's)
- 4) Upcoming HIV/STD Conference
- 5) HIV Training, New ARV Classification Recommendations & FDA Warning on Dolutegravir

Programmatic News Flash

1. Relocation of HIV/STD/TB Program Staff

Notice from the Texas Department of State Health Services

On Friday, July 20, 2018 employees of the TB/HIV/STD Section located in building 636 on the Austin State Hospital (ASH) campus vacated the building. This action was taken in an abundance of caution due to active mold growth in the building. Staff who have moved to other office locations include:

- HIV/STD Prevention and Care Branch (including the Texas HIV Medication Program)
- TB/HIV/STD Epidemiology and Surveillance Branch
- TB and Hansen's Disease Branch

Telephone

- The main telephone number for the Section (512-533-3000) is still in operation. The toll-free Texas HIV Medication Program number (1-800-255-1090) will stay the same.

Email

- ASH 636 staff email addresses will remain the same. Questions for the HIV/STD Program may continue to be emailed to hivstd@dshs.texas.gov.
- Questions for the TB program may continue to be emailed to tb.feedback@dshs.texas.gov.
- TB, HIV, or STD data requests may continue to be emailed to TBHIVSTDdata@dshs.texas.gov.
- HIV prevention data requests may continue to be emailed to HIVTesting_DataRq@dshs.texas.gov.
- Technical assistance requests for ARIES (AIDS Regional Information and Evaluation System) may continue to be emailed to ARIESHelp@dshs.texas.gov.

Fax

- Texas HIV Medication Program (THMP) faxes should be sent to:
- Eligibility- (512) 533-3178
- Medication Orders- (512) 533-3171

2. Ryan White Administrative Agency, Service Delivery Renewal 2018-2019

- 2018-2019 RWSD renewal documents were inadvertently not posted to the website. They are now available at: <http://www.dshs.texas.gov/hivstd/funding/>

3. Frequently Asked Questions (FAQ's)

- HIV Care Services is working on new FAQs for the Part B Standards of Care and they should be available on the DSHS website in a couple of months.

4. Register Now for the DSHS HIV/STD Conference

- 2018 Texas HIV-STD Conference: November 27-29, 2018 at the JW Marriott Hotel, Austin, Texas: The goal of the 2018 Texas HIV/STD Conference is to educate and inform HIV/STD health professionals who serve Texans living with and affected by HIV and other STDs. Conference details, agenda and registration available at: <https://www.dshs.texas.gov/hivstd/conference/2018/>

Clinical New Flash

5. HIV Training, New ARV Classification Recommendations & FDA Warning on Dolutegravir

- **Looking for HIV Training for New Staff?** The South Central AETC in Dallas recommends the Basic HIV Primary Care Module as a good place to start for new staff. See; <https://www.hiv.uw.edu/> their HIV Curriculum is endorsed by all of the AIDS Education Training Centers, (AETC's) and provides no cost CME and CNE's.
- **Starting Clients on ARV?** U. S. Department of Health and Human Services classifications of ART regimens recommended for initial therapy have been changed from: *Recommended, Alternative, and Other* to: *Recommended Initial Regimens for Most People with HIV; and Recommended Initial Regimens in Certain Clinical Situations*. Specific regimens are listed in table 6 of the guidelines. <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0>.
- **What is the New Recommended Therapy?** Integrase strand transfer inhibitor (INSTI) based regimens are recommended as initial therapy for most people with HIV. Non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) based regimens, including darunavir based regimens, are recommended in certain clinical situations
- **Dolutegravir (DTG) - FDA Warning:** New Warning and Recommendations about the use of Dolutegravir in adults and Adolescents with HIV who are Pregnant or of Child-Bearing Potential. Also, for individuals not known to be pregnant, documentation of a negative pregnancy test (see DSHS 2017 Clinical Guidelines) is recommended prior to initiating DTG. Those who are currently receiving DTG as a component of their ART or who wish to be started on DTG should be counseled about the potential risk when DTG is taken near the time of conception. For detailed guidance see table at: <https://aidsinfo.nih.gov/news/2109/recommendations-regarding-the-use-of-dolutegravir-in-adults-and-adolescents-with-hiv-who-are-pregnant-or-of-child-bearing-potential>